A systematic review on the changes in metabolism caused by adjuvant chemotherapy and/or aromatase inhibitors in the treatment of breast cancer (BC). We find a trend of increase in glucose and insulin. This could potentially lead to increased risk of cardiometabolic disease of BC treatment.
Abstract
Introduction
Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long‐term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence.
Methods
We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC.
Results
A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC.
Discussion
Due to methodological limitations including short follow‐up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high‐risk of developing cardiometabolic disease after BC treatment.
https://ift.tt/2Cj39Fp
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.